COMMERCIAL SUPPLY AGREEMENT
PolyPeptide Laboratories, Inc.
365 Maple Ave, Torrance
PolyPeptide Laboratories (SWEDEN) AB
PO Box 30089
Ironwood Pharmaceuticals, Inc.
320 Bent Street
Cambridge, MA 02141
Forest Laboratories, Inc.
909 Third Avenue
New York, New York 10022
[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted
version of this exhibit has been filed separately with the Commission.
This Agreement is entered into on the 23
day of June, 2010 (the “ Effective Date ”), among PolyPeptide
Laboratories Inc., a Delaware corporation with its principal offices at 365 Maple Avenue, Torrance, CA 90503,
USA (“ PPL Inc .”) and PolyPeptide Laboratories AB, a Swedish corporation having a place of business at PO
Box 30089, SE-20061 LIMHAMN, Sweden (“ PPL AB ”) (PPL Inc. and PPL AB are hereinafter jointly
referred to as POLYPEPTIDE ), and Ironwood Pharmaceuticals, Inc., a Delaware corporation with its principal
offices at 320 Bent Street, Cambridge, MA 02141 (“ IRONWOOD ”) and Forest Laboratories, Inc., a
Delaware corporation with its principal offices at 909 Third Avenue, New York, New York 10022 (“ FOREST
”) (IRONWOOD and FOREST are hereinafter jointly referred to as “ CUSTOMER ”).
Whereas, POLYPEPTIDE has developed or acquired patented and non-patented inventions, manufacturing
and testing practices and procedures, and know-how, relating to the manufacture and testing of peptides,
including PRODUCT (defined below), and possesses production facilities for large scale manufacturing of
Whereas, IRONWOOD owns proprietary rights to linaclotide and compositions thereof, analytical methods
related to linaclotide and methods of making and using linaclotide;
Whereas, IRONWOOD and FOREST are parties to that